Superseded public profile

Approval reported abroad↗↗Metabolic↗

Superseded · version 3: Mazdutide↗

Related names recorded in this version: IBI362, LY3305677↗

A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

The previous profile used an unqualified investigational status. We added dated local-government reports of approval in China while keeping national decision and label verification open. Earlier trial-based versions remain available. 23

What this version reported

These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.↗↗

Organizations named in cited records:
  • West China Hospital↗

Trial records: NCT07718126

Sources for this version

  1. 1
    Pre-hepatectomy Rehabilitation in Living Liver Donors With Mazdutide · record history version 1 · last update posted 2026-07-21 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    June 27, 2025 government report of Chinese approval for mazdutide weight management ↗

    Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026

  3. 3
    December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗

    Suzhou Municipal Government · Official source · Source checked September 15, 2026